---

Lymph Node Dissection in Advanced Ovarian Cancer: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)

A Comprehensive Evidence-Based Overview

---

1. Anatomical Background & Lymphatic Drainage of the Ovary

---

2. Incidence of Lymph Node Involvement in Advanced Ovarian Cancer

2.1 Overall LN Positivity by Stage

• Haller et al. (2011, PMID 21721192): In 173 patients with pelvic + para-aortic systematic lymphadenectomy - serous ovarian cancer had 59.3% LN positivity vs 14.4% for non-serous tumors.
• LION trial (2019, PMID 30811909): Among 323 patients randomized to lymphadenectomy, 56% had subclinical nodal metastases despite being clinically and radiographically node-negative.
• Atallah et al. (2021, PMID 34821515): In 184 patients - 70% had both pelvic AND para-aortic involvement; 16% had isolated pelvic nodes; 14% had isolated para-aortic nodes.

2.2 Predictors of LN Metastasis

---

3. Isolated Para-Aortic Lymph Node Involvement (Key Topic)

3.1 Incidence

3.2 Mechanism Explaining Isolated PA-LN

• Para-aortic nodes can harbor disease while pelvic nodes remain negative
• Pelvic lymphadenectomy alone would miss these skip metastases
• Both pelvic AND para-aortic lymphadenectomy (to the level of the left renal vein) is required for complete lymph node staging

3.3 FIGO Staging: LN Involvement

---

4. The Central Question: Should Systematic Lymphadenectomy Be Performed?

1. Context of nodal status (clinically negative vs. enlarged/suspicious nodes)
2. Setting (primary debulking vs. interval debulking)
3. Completeness of intra-abdominal cytoreduction (complete resection vs. residual disease)

---

5. Evidence for Lymphadenectomy in Primary Debulking Surgery (PDS)

5.1 Key Landmark Trials

LION Trial (PMID 30811909) - The Practice-Changing RCT (NEJM 2019)

Bottom line: Even though 56% of patients had occult nodal disease, removing those nodes provided NO survival benefit and significantly increased morbidity and mortality.

Prior RCT - Du Bois et al. (JNCI 2005) - Italian/German Cooperative Trial

5.2 Meta-Analyses Synthesizing Evidence

---

6. Evidence for Lymphadenectomy During Interval Debulking Surgery (IDS)

6.1 Unique Considerations for IDS

• LN shrinkage may make clinically positive nodes appear normal
• LN histology shows variable response to platinum/taxane (some have complete pathological response; others show viable tumor)
• Post-NACT, overall LN positivity rate still 40-67% depending on series

6.2 Caruso et al. 2022 - Systematic Review/Meta-analysis on IDS (PMID 35882606)

Conclusion: SyLND at IDS fails to improve PFS or OS and significantly increases severe complications, lymphocele, and lymphedema.

6.3 PDS vs. IDS: Comparison of LND Evidence

┌─────────────────────────────────────────────────────────────┐
│         LYMPHADENECTOMY IN ADVANCED OVARIAN CANCER          │
│                  Decision Framework                          │
├───────────────────────────┬─────────────────────────────────┤
│    PRIMARY DEBULKING (PDS) │   INTERVAL DEBULKING (IDS)      │
├───────────────────────────┼─────────────────────────────────┤
│ LION RCT (Level 1 evidence)│ Caruso et al. 2022 meta-analysis│
│                           │ (Level 2 evidence - retrospective)│
├───────────────────────────┼─────────────────────────────────┤
│ Clinically/radiologically │ After 3-6 cycles NACT           │
│ negative nodes:           │ Radiologically negative nodes:  │
│ NO SYSTEMATIC LND         │ NO SYSTEMATIC LND               │
│ (no OS/PFS benefit;       │ (no OS/PFS benefit;             │
│  ↑mortality 3x,           │  ↑complications, lymphocele,    │
│  ↑reoperation 2x)         │  lymphedema)                    │
├───────────────────────────┼─────────────────────────────────┤
│ Clinically enlarged/      │ Residual enlarged/suspicious    │
│ suspicious nodes:         │ nodes (biopsy-proven or imaging)│
│ RESECT ENLARGED NODES     │ SELECTIVE RESECTION             │
│ (to achieve complete      │ (to achieve complete resection) │
│ cytoreduction)            │                                 │
└───────────────────────────┴─────────────────────────────────┘

---

7. International Guidelines Summary

7.1 For Advanced-Stage Disease (Stage III-IV) - Systematic Review of Guidelines

7.2 Specific ESGO-ESMO-ESP 2024 Recommendations

"Systematic pelvic and para-aortic lymphadenectomy should not be carried out in patients with advanced disease who have undergone intra-abdominal macroscopically complete resection and have non-suspicious lymph nodes both on preoperative imaging and intraoperative clinical evaluation."

"Enlarged or suspicious lymph nodes should be removed to achieve complete resection."

"The impact of resection of suspicious or enlarged extra-abdominal lymph nodes remains unclear but should be considered if complete macroscopic resection can be achieved intra-abdominally."

---

8. Morbidity of Systematic Lymphadenectomy

---

9. Special Scenarios and Nuances

9.1 When to Resect Lymph Nodes (Current Consensus)

CLINICAL DECISION ALGORITHM - Lymph Node Management in Advanced EOC

Preoperative Assessment
        │
        ├─── CT/PET-CT: Enlarged or suspicious LN?
        │         │
        │         YES ──→ Plan resection of enlarged nodes
        │         │       (regardless of complete intra-abdominal cytoreduction)
        │         NO ──→ Reassess intraoperatively
        │
Intraoperative Assessment
        │
        ├─── Palpable, firm, enlarged LN?
        │         │
        │         YES ──→ Resect to achieve complete cytoreduction
        │         NO ──→ NO systematic lymphadenectomy
        │
        └─── Complete macroscopic intra-abdominal resection achieved?
                  │
                  YES ──→ NO systematic LND (LION principle)
                  NO ──→ Systematic LND will not improve survival
                          with residual disease present

9.2 Histotype-Specific Considerations

9.3 Role of Systematic LND When Complete Resection is NOT Achieved

9.4 Sentinel Lymph Node (SLN) Biopsy - Emerging Role

• Technical challenges: dual primary drainage routes (pelvic + para-aortic via ovarian vessels)
• Detection rates reported 50-85% in small series
• Not yet recommended in guidelines for ovarian cancer
• May have a future role in apparent early-stage disease
• A 2025 study (PMID 40848520) noted challenges beyond simple nodal mapping

---

10. Evidence Hierarchy Summary

---

11. Unresolved Controversies and Future Directions

1. The "suspicious node" definition problem: Guidelines say to remove suspicious/enlarged nodes, but there is no validated size cutoff or imaging criterion. What is "suspicious" intraoperatively remains subjective.
2. LION selection bias concern: Of ~5,000 patients screened, only 647 were randomized - raising questions about generalizability. Many had nodes removed pre-randomization if enlarged, limiting conclusions to truly "clinically negative" nodes.
3. Molecular subtypes: BRCA1/2-mutated HGSOC may have different LN biology - no subgroup data yet to guide histotype-specific recommendations.
4. Imaging accuracy pre-NACT: PET-CT shows 50-70% sensitivity for nodal metastases. A PET-positive node becoming PET-negative after NACT - should it be resected? No RCT data.
5. LGSC controversy: Given ~73% LN positivity in LGSC and its different biology (chemoresistant, endocrine-sensitive), some argue systematic LND retains a role for this subtype.
6. Cardiophrenic lymph nodes: In stage IVA/IVB, resection of cardiophrenic nodes (discussed at ESGO 2026) as part of upper abdominal cytoreduction - role poorly defined.

---

12. Practical Summary for Clinical Decision-Making

---

Key Takeaways

1. The LION trial (NEJM 2019) is the definitive evidence - systematic pelvic + para-aortic lymphadenectomy in advanced EOC with complete intra-abdominal resection and negative nodes provides no OS or PFS benefit despite removing disease in 56% of patients, and significantly increases postoperative mortality.
2. "No systematic LND" does NOT mean "leave enlarged nodes in place" - all guidelines mandate removal of enlarged or suspicious nodes to achieve complete cytoreduction.
3. Isolated para-aortic LN metastasis occurs in ~11-16% of node-positive patients due to direct ovarian-to-para-aortic lymphatic drainage, forming the anatomical rationale for complete retroperitoneal staging in early-stage disease.
4. In IDS, the evidence is of lower quality (retrospective studies only) but consistently shows no benefit from systematic LND, with significant morbidity. No RCT has specifically addressed IDS lymphadenectomy.
5. The therapeutic paradox: Lymph nodes harbor micrometastatic disease in >50% of cases, yet removing them does not improve outcomes - likely because systemic chemotherapy adequately addresses residual nodal micrometastases while the morbidity of dissection negates any surgical benefit.

---